Xiamen Innovax Biotech

This article reads like a press release or a news article and may be largely based on routine coverage. Please help improve this article and add independent sources. (July 2021)

Xiamen Innovax Biotech CO., LTD. (Innovax) is a Chinese company that manufactures, markets, and develops vaccines. It is headquartered in Xiamen, Fujian, China.^[1][2]

In October 2012, Xiamen created the HEV 239 vaccine to treat Hepatitis E. The vaccine was approved by the Chinese Ministry of Science and Technology after it was tested during a controlled trial of 100,000+ people from the Jiangsu Province over a 12-month period. Of the 100,000 people treated, none were infected as compared to 15 that were infected from the controlled placebo group.^[3][4][5]

The firm also has created a cervical cancer vaccine that is currently under a phase III clinical trial,^[6] a genital warts vaccine that is under a phase II clinical trial,^[7] and a 9-valent HPV vaccine currently in the process of receiving clinical approval.^[8]

The World Health Organization (WHO) stated that the Phase I, II, and III clinical trials were effective and safe in healthy subjects, however the WHO has not made a recommendation regarding the HEV 239 Vaccine because of a lack of evidence in people 16 years of age or younger, and 65 years of age and older. China is currently the only country to approve the vaccine since Hepatitis E is rare in developed countries. There are further clinical trials planned before making the drug more generally available. to susceptible populations.^[9] The position of the WHO is that, however, national authorities may decide to use the vaccine based on the local epidemiology.^[9]